Cargando…

Anti-Angiogenic Drugs Inhibit Interstitial Lung Disease Progression in Patients With Advanced Non-Small Cell Lung Cancer

BACKGROUND: Interstitial lung disease (ILD) is the most serious complication of chemotherapy in lung cancer patients with pre-existing ILD. The effect of anti-angiogenic drugs in lung cancer patients with ILD remains unclear. We examined the effect of anti-angiogenic drugs on reducing the risk of IL...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Yanning, Gong, Xiaoling, Hu, Yuxuan, Yi, Qing, Zhang, Qianning, Miao, Liyun, Zhou, Yujie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9251331/ https://www.ncbi.nlm.nih.gov/pubmed/35795057 http://dx.doi.org/10.3389/fonc.2022.873709

Ejemplares similares

Association of Brain Metastases With Immune Checkpoint Inhibitors Efficacy in Advanced Lung Cancer: A Systematic Review and Meta-Analysis
por: Wang, Yanning, et al.
Publicado: (2021)

The Efficacy and Safety of First-Line Chemotherapy in Patients With Non-small Cell Lung Cancer and Interstitial Lung Disease: A Systematic Review and Meta-Analysis
por: Wang, Yanning, et al.
Publicado: (2020)

The Predictive Value of Pretreatment Lactate Dehydrogenase and Derived Neutrophil-to-Lymphocyte Ratio in Advanced Non-Small Cell Lung Cancer Patients Treated With PD-1/PD-L1 Inhibitors: A Meta-Analysis
por: Zhang, Qianning, et al.
Publicado: (2022)

Combination of Immune Checkpoint Inhibitors and Anti-Angiogenic Agents in Brain Metastases From Non-Small Cell Lung Cancer
por: Fang, Likui, et al.
Publicado: (2021)

Novel Angiogenic Regulators and Anti-Angiogenesis Drugs Targeting Angiogenesis Signaling Pathways: Perspectives for Targeting Angiogenesis in Lung Cancer
por: Li, Yingying, et al.
Publicado: (2022)

CT-Based Sarcopenic Nomogram for Predicting Progressive Disease in Advanced Non-Small-Cell Lung Cancer
por: Yi, Xiaoping, et al.
Publicado: (2021)

The Anti-Angiogenic Effects of Anti-Human Immunodeficiency Virus Drugs
por: Barillari, Giovanni
Publicado: (2020)

Clinical progress of anti-angiogenic targeted therapy and combination therapy for gastric cancer
por: Xu, Donghan, et al.
Publicado: (2023)

Research Progress on the Microenvironment and Immunotherapy of Advanced Non-Small Cell Lung Cancer With Liver Metastases
por: Fang, Yujia, et al.
Publicado: (2022)

Immunotherapy progress and clinical strategy of unresectable locally advanced non-small cell lung cancer
por: Zhang, Xiaofei, et al.
Publicado: (2023)

Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer
por: Wiest, Nathaniel, et al.
Publicado: (2021)

Recent advances of nanomaterial-based anti-angiogenic therapy in tumor vascular normalization and immunotherapy
por: Xiao, Mingshu, et al.
Publicado: (2022)

Efficacy and Safety of Anlotinib-Containing Regimens in Advanced Non-Small Cell Lung Cancer: A Real-World Study
por: Sun, Lei, et al.
Publicado: (2023)

Prognostic Impact of the Angiogenic Gene POSTN and Its Related Genes on Lung Adenocarcinoma
por: Sun, Dongfeng, et al.
Publicado: (2022)

Recent advances on anti-angiogenic multi-receptor tyrosine kinase inhibitors in osteosarcoma and Ewing sarcoma
por: Fleuren, Emmy D. G., et al.
Publicado: (2023)

Anti-angiogenic agents in the treatment of non-small cell lung cancer
por: Szyszka-Barth, Katarzyna, et al.
Publicado: (2014)

Anti-Angiogenic Therapy in the Treatment of Non-Small Cell Lung Cancer
por: Tian, Wentao, et al.
Publicado: (2020)

Resistance Mechanisms to Anti-angiogenic Therapies in Cancer
por: Haibe, Yolla, et al.
Publicado: (2020)

Prospect of immunotherapy combined with anti-angiogenic agents in patients with advanced non-small cell lung cancer
por: Liang, Hongge, et al.
Publicado: (2019)

Progression Patterns, Treatment, and Prognosis Beyond Resistance of Responders to Immunotherapy in Advanced Non-Small Cell Lung Cancer
por: Xu, Yanjun, et al.
Publicado: (2021)

Chemotherapy Reverses Anti-PD-1 Resistance in One Patient With Advanced Non-small Lung Cell Cancer
por: Zhao, Lingdi, et al.
Publicado: (2020)

Current Management and Progress in Radiotherapy for Small Cell Lung Cancer
por: Tjong, Michael C., et al.
Publicado: (2020)

Immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer: A review
por: Hao, Yuxuan, et al.
Publicado: (2022)

Development and validation of a m(6)A -regulated prognostic signature in lung adenocarcinoma
por: Chen, Yaxin, et al.
Publicado: (2022)

Corrigendum: Development and validation of a m(6)A -regulated prognostic signature in lung adenocarcinoma
por: Chen, Yaxin, et al.
Publicado: (2023)

Anti-Tumoral and Anti-Angiogenic Effects of Low-Diluted Phenacetinum on Melanoma
por: Fuselier, Camille, et al.
Publicado: (2021)

Interactions Between Anti-Angiogenic Therapy and Immunotherapy in Glioblastoma
por: Jain, Saket, et al.
Publicado: (2022)

Cell adhesion molecules and immunotherapy in advanced non-small cell lung cancer: Current process and potential application
por: Yang, Hongjian, et al.
Publicado: (2023)

Research Progress on RET Fusion in Non-Small-Cell Lung Cancer
por: Zhao, Lu, et al.
Publicado: (2022)

Progress and perspectives of perioperative immunotherapy in non-small cell lung cancer
por: Peng, Yurong, et al.
Publicado: (2023)

Newly developed anti-angiogenic therapy in non-small cell lung cancer
por: Qu, Jingjing, et al.
Publicado: (2017)

An updated network meta-analysis of EGFR-TKIs and combination therapy in the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer
por: Qi, Yuexiao, et al.
Publicado: (2022)

KRAS-Mutant Non-Small Cell Lung Cancer: An Emerging Promisingly Treatable Subgroup
por: Xie, Mingying, et al.
Publicado: (2021)

A CT-Based Radiomics Approach to Predict Nivolumab Response in Advanced Non-Small-Cell Lung Cancer
por: Liu, Chang, et al.
Publicado: (2021)

NTRK Fusion in Non-Small Cell Lung Cancer: Diagnosis, Therapy, and TRK Inhibitor Resistance
por: Liu, Fangfang, et al.
Publicado: (2022)

Pemetrexed for advanced non-small cell lung cancer patients with interstitial lung disease
por: Kato, Motoyasu, et al.
Publicado: (2014)

Vascular phenotype in angiogenic and non-angiogenic lung non-small cell carcinomas
por: Passalidou, E, et al.
Publicado: (2002)

Opportunities and Challenges of Nanoparticles in Digestive Tumours as Anti-Angiogenic Therapies
por: Yang, Zhengyang, et al.
Publicado: (2022)

Resistance Mechanisms of the Metastatic Tumor Microenvironment to Anti-Angiogenic Therapy
por: Schiffmann, Lars M., et al.
Publicado: (2022)

Current and emerging anti-angiogenic therapies in gastrointestinal and hepatobiliary cancers
por: Saoudi González, Nadia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2pukbeai49tefpffc95l5vn0lp